Vitiligo
Conditions
Interventions
Ruxolitinib:N/A
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged 12 years or older, any gender; 2. Sign the "Informed Consent Form"; 3. Clinically diagnosed with non-segmental vitiligo; 4. Vitiligo affecting less than 10% of the body surface area; 5. Agree to discontinue all other vitiligo-related treatments from the screening visit until the final follow-up visit; 6. Female participants must have no plans for pregnancy or egg donation from the screening period until 4 weeks after the last dose and voluntarily adopt effective physical contraception. Male participants must have no plans for fatherhood or sperm donation from the screening period until 4 weeks after the last dose and voluntarily adopt effective physical contraception. Effective physical contraceptive methods include: barrier methods such as condoms or cervical caps (diaphragms or cervical shields); placement of intrauterine devices (IUD) or intrauterine systems (IUS); participants or their partners who have undergone surgical sterilization at least 6 months prior to first use of the study medication (including bilateral oophorectomy with or without hysterectomy, total hysterectomy, tubal ligation, or vasectomy); and other effective physical contraception methods deemed reasonable by the investigator.
Exclusion criteria
Exclusion criteria: 1.Allergy to ruxolitinib cream; 2.Pregnant or lactating women; 3.Any condition deemed inappropriate for study participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total vitiligo area scoring index,T-VASI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vitiligo Noticeability, VNS;T-VASI 50/75/90;Safety ;Vitiligo-specific quality-of-life, VitiQoL;F-VASI 50/75/90; | — |
Countries
China
Contacts
Public ContactJinzhu Guo
Peking University Third Hospital
Outcome results
None listed